What is Semax nasal spray?
Semax nasal spray is the standard clinical form of Semax administration. The preparation consists of a peptide dissolved in a sterile aqueous solution and administered as drops or a fine mist directly into the nasal cavity. This is the form in which Semax has been used in Russian clinical practice since its registration in Russia in the 1990s, for the treatment of ischemic stroke, cerebrovascular insufficiency, and diseases of the optic nerve. It is also the method of administration used in most published clinical trials on humans.
The nasal spray format was specifically chosen because it allows the peptide to travel directly from the nasal cavity to the brain via the olfactory pathway—the neural network responsible for the sense of smell. This direct route bypasses the need for the peptide to cross the blood-brain barrier through the bloodstream and avoids gastrointestinal degradation, which would destroy the peptide if it were swallowed.
It is worth emphasizing that Semax nasal spray and Semax for injection contain exactly the same active molecule. The difference lies solely in the method of peptide delivery to the body and the effectiveness of its reach to the brain—which has significant implications for dosage, duration of action, and effect profile. The nasal route promotes cerebral effects due to direct access to the brain, whereas injection routes deliver the peptide first to the general bloodstream, causing broader distribution to both the brain and peripheral tissues.
How does the Semax nasal spray reach the brain?
Semax nasal spray reaches the brain via the olfactory pathway—a direct anatomical shortcut from the nasal cavity to brain tissue that completely bypasses the blood-brain barrier. When the spray is administered and the liquid contacts the upper nasal mucosa—the moist inner lining of the nasal cavity—the olfactory epithelium absorbs the peptide. The olfactory epithelium is a specialized tissue in the upper part of the nasal cavity that contains the nerve endings responsible for the sense of smell. From there, Semax travels along the olfactory nerve fibers directly to the olfactory bulb—the brain’s first smell-processing center—and then on to deeper brain structures.
Pharmacokinetic studies using a radioactively labeled version of Semax confirmed that approximately 0.093% of the administered dose per gram of brain tissue was detectable as early as 2 minutes after intranasal administration. Approximately 80% of this early brain radioactivity represented intact Semax, rather than its metabolic products [1]. This exceptionally rapid access to the brain—measurable concentrations in the brain within just 2 minutes—demonstrates that the intranasal-to-brain pathway is highly rapid and efficient for this peptide.
The olfactory pathway is not the only way that intranasally administered Semax reaches the brain. Some absorption also occurs through the nasal mucosa into the general bloodstream, from where the peptide can cross the blood-brain barrier via systemic circulation—although this indirect route is slower and delivers lower concentrations to the brain. The trigeminal nerve pathway—another neural network running directly from the nasal cavity to the brainstem—offers a third direct route. The combination of these pathways means that intranasal Semax achieves significant concentrations in brain tissue, which would be difficult to obtain through systemic injection without using significantly higher doses. This is why the intranasal route elicits stronger cognitive effects per unit dose than intraperitoneal or subcutaneous injection [2].
How effective is Semax nasal spray?
Semax nasal spray is effective in inducing cognitive, neuroprotective, and neurobiological effects documented in published studies. In clinical stroke trials, intranasal Semax at daily doses of 12–18 milligrams accelerated neurological recovery, improved motor functions, and elevated plasma BDNF levels in human patients [3], [4]. In patients with optic nerve diseases, Semax administered to the nasal mucosa improved visual acuity, expanded the visual field, and enhanced the electrical sensitivity and conductivity of the optic nerve [5].
In healthy volunteers, intranasal Semax induced measurable changes in the default mode network in resting-state functional MRI studies as early as 5 minutes after administration [6]. This confirms the rapid and significant engagement of the brain following intranasal administration.
Animal studies consistently show strong effects after intranasal administration, including increased BDNF in the hippocampus [7], behavioral changes that reduce anxiety and are antidepressant-like [8], and improvements in learning and memory tasks [2].
What is the difference between 0.1% and 1% Semax nasal spray?
The difference between 0.1% and 1% Semax nasal spray is a tenfold difference in peptide concentration—one is ten times stronger than the other—which directly determines the amount of Semax delivered per drop or spray. The 0.1% solution contains 1 milligram of Semax per milliliter of liquid. The 1% solution contains 10 milligrams of Semax per milliliter. This difference in concentration has direct practical implications for dosing precision and determines which clinical or research applications each concentration is suitable for. Both concentrations have been used in published studies and in Russian clinical practice.
In Russian clinical practice, a concentration of 1%—10 milligrams per milliliter—is the standard formulation used in the treatment of ischemic stroke, where relatively high daily doses of 12–18 milligrams are required [3]. A concentration of 0.1% — 1 milligram per milliliter — is used in contexts requiring lower doses, such as in the treatment of optic nerve diseases [5] and in applications where more precise control of lower doses is desired.
How many micrograms per drop does Semax nasal spray deliver?
The amount of Semax delivered per drop depends on two factors: the concentration of the solution and the volume of each drop. Standard pharmaceutical nasal droppers deliver approximately 50 microliters per drop — microliters are thousandths of a milliliter — although this can vary slightly depending on the design of the dropper bottle.
Using this standard drop volume as a reference: a 0.1% solution delivers approximately 50 micrograms per drop, while an 1% solution delivers approximately 500 micrograms per drop.
These calculations provide approximate values based on standard drop volumes. In a pharmacokinetic study investigating intranasal administration of Semax, a dose of 50 micrograms per kilogram body weight in rats was administered in a volume of 20 microliters [1].
It is important that converting rat doses to equivalent human doses requires complex pharmacokinetic adjustments that cannot be made by simple body weight multiplication. No published study has formally established equivalent human doses through pharmacokinetic bridging studies.
What concentration should be used?
The appropriate concentration depends entirely on the intended dose and the volume that can be comfortably administered into the nasal cavity. A practical limitation is that the total volume administered intranasally should remain small. Large volumes are uncomfortable, tend to drip into the throat rather than be absorbed by the nasal mucosa, and are less efficiently absorbed via the olfactory pathway. Maintaining a total intranasal volume of approximately 100–200 microliters—roughly 2–4 drops per nostril—is a practical upper limit for comfortable and efficient intranasal absorption. This means that higher doses require higher concentrations to deliver the desired amount of peptide within an absorbable volume.
It should be emphasized that the above information is pharmacological and practical in nature — it does not constitute a recommendation for self-administration of Semax. The appropriate concentration for individual use in a clinical context is a decision for a qualified healthcare professional. Semax is not approved for self-administration in most countries.
How is Semax nasal spray administered?
In published clinical studies and Russian clinical practice, Semax nasal spray is administered as drops applied directly to the nasal mucous membrane. The patient is typically positioned with their head tilted back slightly so that the drops contact the upper nasal epithelium—a specialized tissue in the upper part of the nasal cavity where the olfactory nerve endings are most concentrated.
The correct anatomical target is the olfactory region in the upper part of the nasal cavity—not the inferior nasal passages where most nasal sprays are directed—because it is this superior region that contains the olfactory epithelium, through which direct nose-to-brain transport occurs.
In clinical trials, daily doses were divided into multiple administrations throughout the day. In a stroke efficacy study, daily doses of 12 milligrams for moderate strokes and 18 milligrams for severe strokes were administered in two 10-day courses, with a 20-day interval between courses [3]. In a clinical trial of optic nerve diseases, Semax was administered either as nasal drops or via intranasal electrophoresis—a technique using a mild electrical current to drive the solution deeper into the nasal mucosa—with the electrophoresis group showing the most pronounced and sustained improvements [5].
How long does Semax nasal spray take to be absorbed?
Semax achieves measurable concentrations in the brain within 2 minutes of nasal administration, according to a pharmacokinetic study with radioactive labeling [1]. This makes it one of the fastest absorbing administration methods for any neuroactive compound.
The subjective onset of cognitive effects reported by users typically corresponds to this rapid pharmacokinetic profile, with changes in mental clarity and alertness often reported within 15–30 minutes. At the gene expression level, measurable changes in BDNF and NGF mRNA were detectable in rat brain tissue as early as the earliest measured time point—20 minutes after a single intranasal dose [9]. This confirms that the biological cascade induced by Semax entry into the brain begins very rapidly after administration.
Can you make Semax nasal spray yourself?
Reconstituting lyophilized peptide powder—that is, freeze-dried (frozen and vacuum-dried) peptide powder—into a solution for nasal administration is technically feasible but requires careful attention to sterility, accurate measurements, and appropriate preparation conditions. The process involves dissolving a precisely weighed amount of the peptide powder in a measured volume of sterile bacteriostatic water—a sterile aqueous solution containing a small amount of a preservative called benzyl alcohol—or sterile saline to achieve the target concentration. The solution is then transferred to a sterile spray bottle or dropper.
Critical safety requirements are significant. Pharmaceutical-grade sterile water is needed. Precise weighing equipment is required for measuring peptide powder on the milligram scale, as concentration errors can result in dosing errors. A completely sterile preparation environment is essential to prevent bacterial or fungal contamination. Appropriate storage conditions are necessary to maintain the stability and sterility of the solution.
Contamination of nasal preparations with bacteria, fungi, or endotoxins – toxic byproducts of bacterial breakdown – can cause serious local or systemic infections. No published studies have validated protocols for home preparation of Semax nasal spray, and this practice carries inherent risks that professionally manufactured pharmaceuticals are specifically designed to eliminate.
Can Semax be injected?
Yes, Semax can be administered via subcutaneous injection—meaning injection into the fatty layer just under the skin—and this route has been used in some animal studies and is discussed in nootropic communities. However, it is not a standard clinical administration method in published human trials.
Most published research on Semax in humans has used intranasal administration, which provides better delivery to the central nervous system via the direct olfactory pathway. Subcutaneous injection delivers the peptide to the fat layer directly beneath the skin, from which it is absorbed into the bloodstream and distributed throughout the body, reaching the brain by crossing the blood-brain barrier through systemic circulation. This systemic delivery route elicits a different effect profile than intranasal administration—encompassing broader distribution to peripheral tissues, slower brain penetration, and evidence suggesting more pronounced analgesic effects. However, it may elicit relatively weaker cognitive enhancement effects on a per-dose basis [2].
A head-to-head comparative study showed that intraperitoneal administration—injection into the abdominal cavity, a route used solely in studies with distribution similar to subcutaneous injection—elicited analgesic effects absent with nasal administration. Nasal administration, in turn, resulted in a stronger improvement in learning than the systemic route [2]. This route-of-administration-dependent difference in effects is important for understanding why the two administration methods are not simply interchangeable in terms of expected outcomes.
How to prepare Semax for injection?
Preparation of Semax for subcutaneous injection from lyophilized powder requires reconstitution with sterile bacteriostatic water. Bacteriostatic water—containing a small amount of benzyl alcohol as a preservative—is preferable to plain sterile water for multi-dose vials, as the preservative prevents bacterial growth between uses.
The process involves drawing an appropriate volume of bacteriostatic water into a syringe, then slowly injecting it along the wall of the vial containing the lyophilized powder. The water should not be directed at the powder cake itself—the compressed dry mass of the peptide—as this could damage the peptide's structure. The vial is then gently swirled—not vigorously shaken, which can also damage the peptide—until the powder completely dissolves into a clear solution.
The safety requirements for preparing an injection are significantly more stringent than for a nasal preparation. Strict aseptic technique—a sterile, contaminant-free preparation process—is essential to prevent injection site infections or systemic sepsis, a life-threatening infection of the entire body. Accurate concentration calculations are necessary to avoid dosing errors. The reconstituted solution must be visually inspected for particulate matter or turbidity before use, as either would indicate potential contamination or degradation. Proper disposal of used needles and syringes in a puncture-resistant container is also required.
These requirements are not trivial. Injection carries risks of infection, vascular injury, and nerve damage, which nasal administration does not pose.
Where to inject Semax?
Subcutaneous injection sites for Semax are consistent with standard conventions for other subcutaneously administered peptides and for insulin injections. The most commonly used sites are the abdomen at least 2 centimeters from the navel, the outer thigh, or the back of the upper arm. The abdomen is generally preferred due to ease of self-administration and consistent absorption.
The injection should be administered into the subcutaneous tissue layer – the fatty tissue directly beneath the skin – and not into muscle (intramuscular injection) or a blood vessel (intravenous injection), as these are different techniques with different safety profiles. The standard technique involves pinching the skin to lift the subcutaneous tissue away from the muscle beneath, inserting the needle at a 45-degree angle for thin individuals or a 90-degree angle with adequate subcutaneous tissue, slowly injecting, and then withdrawing the needle while releasing the skin pinch.
Injection sites should be rotated with each administration—meaning, use a different site each time—to prevent local tissue irritation or lipohypertrophy, which is hardening and thickening of fat tissue that can develop in a repeatedly used injection site.
What equipment is needed for Semax injection?
Standard subcutaneous injection requires insulin syringes — typically with 29–31 gauge needles, which are very thin, and capacities of 0.5–1 milliliters suitable for small peptide doses. Bacteriostatic water is needed to reconstitute lyophilized powder. Alcohol swabs are used to disinfect the vial's rubber stopper and the skin at the injection site prior to administration. A sharps container — a puncture-resistant container specifically designed for safe needle disposal — is required for the safe disposal of used needles and syringes.
Insulin syringes are particularly suitable for subcutaneous injection of peptides, as their very thin needles minimize discomfort and tissue trauma. Their small volume capacity also matches the small volumes typically required for concentrated peptide solutions.
What doses were used in the studies?
To begin, it must be clearly stated that no published clinical study has established a validated dosing regimen for subcutaneous injection of Semax in humans for any indication. Dosing information available from published studies comes primarily from animal studies using intraperitoneal administration and from Russian clinical practice using intranasal administration. Translation of animal or intranasal clinical doses to subcutaneous doses for humans cannot be performed with scientific precision using currently published data.
In animal studies, intraperitoneal doses ranging from 0.015 to 0.6 milligrams per kilogram of body weight were used to investigate cognitive, anxiolytic, and neuroprotective effects [2], [8], [10]. In Russian clinical practice, intranasal doses of 12–18 milligrams per day have been used for ischemic stroke in divided administrations [3].
The dose-response relationship for subcutaneous Semax in humans—that is, the relationship between the size of the dose and the magnitude of the effect it produces—has not been formally characterized. This means that the range of doses that produce optimal effects versus the range that produces adverse effects remains entirely undefined for this population and this route of administration.
Discussions in nootropic communities typically refer to subcutaneous doses in the range of 200–600 micrograms per injection. This represents user-derived practices based on extrapolations from animal studies and clinical nasal doses—rather than validated human pharmacokinetic or pharmacodynamic data. This context must be clearly understood by anyone evaluating such information.
How often would Semax be injected in research protocols?
In animal studies using intraperitoneal administration, Semax was typically administered once daily [10], [11], which is consistent with the 20–24-hour duration of action reported in early human studies with nasal administration [12].
Russian clinical courses for intranasal Semax typically lasted 10 days, sometimes repeated after a break, rather than involving indefinite continuous daily use. This cyclical approach—using the compound for a set period followed by a break—is consistent with Semax's neurotrophic mechanism, which works by inducing changes in gene expression and stimulating the brain's own growth factor production. These are mechanisms that do not require constant receptor stimulation to elicit lasting neuroplastic changes.
It cannot be determined from published data whether subcutaneous injections in humans would follow a similar daily or cyclical schedule.
Can Semax and Selank be injected together?
Semax and Selank are chemically compatible peptides that could theoretically be mixed in the same syringe for simultaneous administration. Both are water-soluble heptapeptides with no known chemical incompatibilities between them. Enkephalinase inhibition study showed both peptides interact with the same enzyme systems in human serum without apparent interference with each other's activity [13], providing indirect evidence of biochemical compatibility.
However, no published study has formally investigated the pharmacokinetics, stability, or pharmacodynamic interactions of Semax and Selank when mixed in the same solution. Whether one peptide degrades the other under storage or administration conditions — and whether mixing them alters how each performs — remains unknown.
In Russian clinical practice, both peptides are administered intranasally as separate preparations, not as a ready-made mixed preparation. The practical approach used in research settings involves administering each peptide separately—either at different times or via separate administrations—to maintain independent dose control of each compound.
What does research say about the combined effects of Semax and Selank?
The most significant published data regarding the effects of Semax and Selank in combination come from a resting-state functional MRI study of brain connectivity that analyzed both peptides in the same group of 52 healthy participants—although each participant received only one compound per session, not the combination [14]. The study revealed that Selank and Semax induced both shared and unique effects on functional connectivity between the right amygdala and temporal cortical areas. Post-hoc analysis identified both general effects common to both peptides and effects specific to each [14]. The shared effects suggest common pharmacological ground, while the unique effects confirm that each peptide contributes distinct pharmacological actions—providing a scientific basis for why their combination might elicit a broader profile of effects than either alone.
Both peptides inhibit enkephalin-degrading enzymes in human serum, with Semax showing an IC50 of 10 micromolar and Selank an IC50 of 20 micromolar [13]. The combination would therefore be expected to result in greater total inhibition of these enzymes than either peptide alone. Pentapeptide fragments produced when each peptide is degraded within the body also demonstrated independent inhibitory activity, suggesting that the breakdown products of both peptides together would interact with overlapping enzyme and receptor systems in a complex, yet potentially additive, manner [13].
Nasal spray vs. injection for Semax and Selank
The choice between intranasal administration and subcutaneous injection of Semax and Selank involves significant trade-offs in terms of target tissue concentrations, onset of action characteristics, and practical convenience.
Nasal administration provides better direct delivery to the brain via the olfactory pathway — demonstrated by rapid 2-minute brain penetration documented for Semax [1] — and elicits stronger cognitive effects per dose compared to systemic routes [2]. The nasal route is also the only clinically validated human route of administration with published safety and efficacy data from controlled trials.
Subcutaneous injection bypasses the olfactory pathway and delivers both peptides first to the general circulation, leading to broader distribution to peripheral tissues in addition to central brain effects. For Semax, this systemic distribution means greater engagement of receptors outside the brain—including peripheral melanocortin and opioid receptors—potentially eliciting more pronounced effects on pain sensitivity and peripheral immune modulation [2, 15]. For Selank, which exhibits documented immunomodulatory and cytokine-regulating effects relevant in peripheral tissues [16], systemic delivery may be particularly pertinent to these extra-brain actions.
From a practical point of view, intranasal administration is significantly simpler. It does not require injection equipment or sterile preparation techniques, carries no risk of infection from needle use, and produces rapid cognitive effects noticeable within minutes. Subcutaneous injection introduces complexity, infection risk, and practical barriers without a clearly established benefit for cognitive enhancement purposes based on available evidence.
For anyone operating outside a supervised medical context, the nasal route offers a more favorable overall risk-benefit profile based on published literature.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, treatment recommendation, or instruction for self-administration of any compound. Semax and Selank remain research compounds in most countries, including the United States and most European countries, and are not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. They are approved and used clinically in Russia and some Eastern European countries. The administration information presented here reflects clinical and research practices as documented in published literature and is not intended to direct or encourage self-administration. Most evidence comes from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical trials are necessary to more definitively establish safety, efficacy, appropriate dosing, and long-term effects in humans.
References
Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskii, A. A., Levitskaya, N. G., Shevchenko, V. P., Grivennikov, I. A., & Myasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganic Chemistry, 32 (1), 64–70. https://doi.org/10.1134/s1068162006010055
Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. Sechenov Physiological Journal of Russia, 96 (10), 1014–1023. PMID: 21268834 https://pubmed.ncbi.nlm.nih.gov/21268834/
[3] Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke. Journal of Neurology and Psychiatry named after SS Korsakov, 97 (6), 26–34. PMID: 11517472 https://pubmed.ncbi.nlm.nih.gov/11517472/
Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after SS Korsakov, 118 (3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of therapeutic effect of new Russian drug semax in optical nerve disease. Ophthalmology Journal, 116 (1), 15–18. PMID: 10741256
[6] Lebedeva, I.S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165 (5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
Dolotov, O.V., Karpenko, E.A., Seredenina, T.S., Inozemtseva, L.S., Levitskaya, N.G., Zolotarev, Yu. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97 (Suppl 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
[8] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984 , 177068. https://doi.org/10.1016/j.ejphar.2024.177068
Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41 (1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
[10] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioral Physiology, 34 (4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28
[11] Volodina, M. A., Sebentsova, E. A., Glazova, N. Yu., Manchenko, D. M., Inozemtseva, L. S., Dolotov, O. V., Andreeva, L. A., Levitskaya, N. G., Kamensky, A. A., & Myasoedov, N. F. (2012). Correction of long-lasting negative effects of neonatal isolation in white rats using Semax. Acre of Nature, 4 (1), 86–92. PMID: 22708068
[12] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I.P. Pavlov, 47 (2), 420–430. PMID: 9173745
[13] Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganic Chemistry, 27 (3), 180–183. https://doi.org/10.1023/a:1011373002885
[14] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490 (1), 9–11. https://doi.org/10.1134/S001249662001007X
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182 (22), 5489–5516. https://doi.org/10.1111/bph.70122
[16] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16 (2), 162-167. https://doi.org/10.2174/1574884715666200704152810